Friday May 3, 2013 0 commentsDENVER - Kerecis, a medical device company focused on the treatment of tissue damage with Omega3-based regenerative technologies, today announced its recent clinical trial found no allergenic reactions to its fish-skin Marigen Omega3 product.
Forty patients were tested for allergic reactions to the product. Kerecis made the announcement at the Symposium for Advanced Wound Care in Denver.
Kerecis' most advanced product is Marigen Wound, aimed at the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds.
Products based on the Marigen Omega3 technology are intact, decellularized fish skin sheets that have had all cells and antigenic materials removed, Kerecis said.
The products are applied to tissue damage areas where they recruit the body's own cells, are incorporated into the wound, and ultimately are converted into functional, living tissue.
Patents are pending for the technology in several nations around the world, Kerecis said.
"This 40-patient clinical study further demonstrates the safety of the Marigen Omega3 tissue-regeneration technology," said Dr. Baldur Tumi Baldursson, the company's medical director.
"More than 100 patients have now participated in our clinical studies and no one has demonstrated any allergenic or otherwise adverse reaction to the material."
For more information, visit www.kerecis.com.